Fig. 1From: Low titers of SARS-CoV-2 neutralizing antibodies after first vaccination dose in cancer patients receiving checkpoint inhibitorsKinetics of neutralizing antibodies in patients receiving immunotherapy and matched controls after vaccination with the first dose of the BNT162b2, mRNA-1273 and AZD1222 vaccine. On D22, patients had lower production of NAb inhibition titers compared to controls of similar age and gender (see text). Only 6 patients (10.7%) had NAb titers of equal or more than 50%Back to article page